🔎 Trials Near Me

Home › Multiple Myeloma › Missouri

Multiple Myeloma clinical trials in Missouri

26 studies for Multiple Myeloma are looking for participants at sites in Missouri.

Cities in Missouri

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

  • Washington University School Of Medicine, St Louis
RecruitingPhase 4
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT05201781

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

  • Washington University School Of Medicine, St Louis
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT04634552

Collection of Tissue Samples for Cancer Research

  • Washington University - St. Louis, St Louis
RecruitingObservational study
2 Months · All sexes · Updated Sep 16, 2026 · NCT00900198

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

  • Washington University School of Medicine, St Louis
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT06297226

A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma

  • Washington University School of Medicine, St Louis
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT06980480

A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma

  • Research Site, St Louis
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 27, 2026 · NCT07681596

A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)

  • GSK Investigational Site, Bridgeton
  • GSK Investigational Site, Springfield
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 25, 2026 · NCT07227311

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

  • American Oncology Partners, P.A. Dba MidAmerica Cancer Care, Belton
  • MIVA Medical, Independence
  • Kansas City VA Medical Center, Kansas City
  • and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 24, 2026 · NCT06152575

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

  • Mercy Oncology and Hematology - Clayton-Clarkson, Ballwin
  • Central Care Cancer Center - Bolivar, Bolivar
  • Cox Cancer Center Branson, Branson
  • and 19 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT04566328

Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

  • Research Site, St Louis
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 14, 2026 · NCT07764978

Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance

  • Washington University School of Medicine, St Louis
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 6, 2026 · NCT06483100

A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

  • Washington University/Siteman Cancer Center, St Louis
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 6, 2026 · NCT07284758

Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)

  • Washington University School of Medicine, St Louis
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 21, 2026 · NCT07200089

Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)

  • Washington University School of Medicine, St Louis
Recruiting
Ages 18 and older · All sexes · Updated Jul 14, 2026 · NCT06340646

Safety and Efficacy of CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple Myeloma

  • Washington University School of Medicine, St Louis
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 9, 2026 · NCT06185751

Integrated Cancer Repository for Cancer Research

  • Saint Luke's Cancer Institute, East, Kansas City
  • Saint Luke's Cancer Institute, Kansas City
  • Saint Luke's Cancer Institute, Kansas City North, Kansas City
  • and 3 more
RecruitingObservational studyHealthy volunteers welcome
Ages 19 to 110 · All sexes · Updated Jun 29, 2026 · NCT02012699

64Cu-LLP2A for Imaging Hematologic Malignancies

  • Washington University School of Medicine, St Louis
RecruitingEarly phase 1Healthy volunteers welcome
Ages 18 and older · All sexes · Updated Jun 17, 2026 · NCT06636175

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

  • Saint Louis Cancer and Breast Institute-Ballwin, Ballwin
  • Central Care Cancer Center - Bolivar, Bolivar
  • Cox Cancer Center Branson, Branson
  • and 21 more
RecruitingPhase 3
All ages · All sexes · Updated Jun 10, 2026 · NCT05561387

Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma

  • Washington University School of Medicine, St Louis
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 8, 2026 · NCT07200102

An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers

  • Washington University School of Medicine, St Louis
Recruiting
Ages 18 to 99 · All sexes · Updated Jun 1, 2026 · NCT07226934

Post-Op Pain Control for Prophylactic Intramedullary Nailing.

  • Saint Louis University, St Louis
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Apr 22, 2026 · NCT03823534

Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function

  • Washington University School of Medicine, St Louis
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Mar 11, 2026 · NCT06623630

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.